Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes
Jasmine C. Wong, … , Kevin Shannon, Jeffery M. Klco
Jasmine C. Wong, … , Kevin Shannon, Jeffery M. Klco
Published July 25, 2018
Citation Information: JCI Insight. 2018;3(14):e121086. https://doi.org/10.1172/jci.insight.121086.
View: Text | PDF
Research Article Hematology

Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes

  • Text
  • PDF
Abstract

Germline SAMD9 and SAMD9L mutations cause a spectrum of multisystem disorders that carry a markedly increased risk of developing myeloid malignancies with somatic monosomy 7. Here, we describe 16 siblings, the majority of which were phenotypically normal, from 5 families diagnosed with myelodysplasia and leukemia syndrome with monosomy 7 (MLSM7; OMIM 252270) who primarily had onset of hematologic abnormalities during the first decade of life. Molecular analyses uncovered germline SAMD9L (n = 4) or SAMD9 (n = 1) mutations in these families. Affected individuals had a highly variable clinical course that ranged from mild and transient dyspoietic changes in the bone marrow to a rapid progression of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with monosomy 7. Expression of these gain-of-function SAMD9 and SAMD9L mutations reduces cell cycle progression, and deep sequencing demonstrated selective pressure favoring the outgrowth of clones that have either lost the mutant allele or acquired revertant mutations. The myeloid malignancies of affected siblings acquired cooperating mutations in genes that are also altered in sporadic cases of AML characterized by monosomy 7. These data have implications for understanding how SAMD9 and SAMD9L mutations contribute to myeloid transformation and for recognizing, counseling, and treating affected families.

Authors

Jasmine C. Wong, Victoria Bryant, Tamara Lamprecht, Jing Ma, Michael Walsh, Jason Schwartz, Maria del pilar Alzamora, Charles G. Mullighan, Mignon L. Loh, Raul Ribeiro, James R. Downing, William L. Carroll, Jeffrey Davis, Stuart Gold, Paul C. Rogers, Sara Israels, Rochelle Yanofsky, Kevin Shannon, Jeffery M. Klco

×

Figure 5

Proposed roles of SAMD9/9L haploinsufficiency in BM Mo7 and subsequent hematologic outcomes.

Options: View larger image (or click on image) Download as PowerPoint
Proposed roles of SAMD9/9L haploinsufficiency in BM Mo7 and subsequent h...
In accordance with the model proposed by Tesi and colleagues (5), inflammatory stress in the BM microenvironment (yellow thunderbolt) provides selective pressure favoring the outgrowth of Mo7 clones (–7) in carriers of SAMD9/9L GOF mutations. Hematopoietic recovery occurs in many patients due to outgrowth of a residual population of HSPCs without Mo7, which also frequently exhibit revertant SAMD9/9L mutations or somatic UPD (top pathway). This pattern was seen in the members of families 3–5. Our analysis of families 1 and 2, in which both siblings progressed to MDS/AML, supports the existence of an alternative pathway that involves irreversible stress-induced damage to the non-Mo7 HSPC compartment (indicated as crosses). This creates a genetic bottleneck and results in persistence of the Mo7 clone that has a high probability of acquiring a limited spectrum of cooperating mutations that drive progression to leukemia.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts